Home › Stock analysis › PRLD
Prelude Therapeutics (PRLD) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
What changed since yesterday
- Closed at $3.26, -1.81% vs the prior close of $3.32.
- Volume 479.27K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PRLD dips 1.8% to $3.26. Closed at $3.26, -1.81% vs the prior close of $3.32. Day range $3.19–$3.41, opened at $3.32.
Last close$3.26-1.81%
Day range3.19–3.41
Open3.32
Volume479.27K
52-week range1.16–6.83
Avg volume (20d)498.11K
PRLD daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PRLD dips 1.8% to $3.26
- Closed at $3.26, -1.81% vs the prior close of $3.32. Day range $3.19–$3.41, opened at $3.32.
- Volume was 479.27K shares, 0.9x its 50-day average of 517.04K.
- Price is -32.2% vs its 50-day average ($4.81) and -17.5% vs its 200-day average ($3.95).
- 52-week range $1.16–$6.83; today's close sits at 37% of that range, 52.3% below the 52-week high.
Oct 15, 2026 — PRLD rises 2.8% to $3.32
- Closed at $3.32, +2.79% vs the prior close of $3.23. Day range $3.20–$3.44, opened at $3.30.
- Volume was 400.30K shares, 0.8x its 50-day average of 512.20K.
- Price is -31.4% vs its 50-day average ($4.84) and -15.9% vs its 200-day average ($3.95).
- 52-week range $1.16–$6.83; today's close sits at 38% of that range, 51.4% below the 52-week high.
Oct 14, 2026 — PRLD slides 9.3% to $3.23, a 6-month low, 3 down days in a row
- Closed at $3.23, -9.27% vs the prior close of $3.56. Day range $3.20–$3.50, opened at $3.50.
- Volume was 489.00K shares, 1.0x its 50-day average of 506.79K.
- Price is -33.6% vs its 50-day average ($4.86) and -18.2% vs its 200-day average ($3.95).
- 52-week range $1.16–$6.83; today's close sits at 37% of that range, 52.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PRLD slides 4.8% to $3.56, a 3-month low
- Closed at $3.56, -4.81% vs the prior close of $3.74. Day range $3.43–$3.90, opened at $3.74.
- Volume was 674.40K shares, 1.4x its 50-day average of 499.08K.
- Price is -27.2% vs its 50-day average ($4.89) and -9.7% vs its 200-day average ($3.94).
- 52-week range $1.16–$6.83; today's close sits at 42% of that range, 47.9% below the 52-week high.
Oct 12, 2026 — PRLD slides 3.9% to $3.74
- Closed at $3.74, -3.86% vs the prior close of $3.89. Day range $3.74–$3.94, opened at $3.91.
- Volume was 196.50K shares, 0.4x its 50-day average of 501.00K — lighter than usual.
- Price is -23.8% vs its 50-day average ($4.91) and -5.0% vs its 200-day average ($3.94).
- 52-week range $1.15–$6.83; today's close sits at 46% of that range, 45.2% below the 52-week high.
Oct 9, 2026 — PRLD ends flat (+0.3%) to $3.89, 5 up days in a row
- Closed at $3.89, +0.26% vs the prior close of $3.88. Day range $3.85–$4.03, opened at $3.87.
- Volume was 341.60K shares, 0.7x its 50-day average of 500.76K.
- Price is -21.0% vs its 50-day average ($4.92) and -1.0% vs its 200-day average ($3.93).
- 52-week range $1.15–$6.83; today's close sits at 48% of that range, 43.0% below the 52-week high.
- That makes 5 straight gains.
Oct 8, 2026 — PRLD rises 1.3% to $3.88, 4 up days in a row
- Closed at $3.88, +1.31% vs the prior close of $3.83. Day range $3.66–$3.95, opened at $3.77.
- Volume was 423.50K shares, 0.8x its 50-day average of 502.00K.
- Price is -21.6% vs its 50-day average ($4.95) and -1.1% vs its 200-day average ($3.92).
- 52-week range $1.15–$6.83; today's close sits at 48% of that range, 43.2% below the 52-week high.
- That makes 4 straight gains.
Oct 7, 2026 — PRLD rises 0.5% to $3.83, 3 up days in a row
- Closed at $3.83, +0.52% vs the prior close of $3.81. Day range $3.69–$3.93, opened at $3.84.
- Volume was 454.60K shares, 0.9x its 50-day average of 530.02K.
- Price is -22.8% vs its 50-day average ($4.96) and -2.1% vs its 200-day average ($3.91).
- 52-week range $1.15–$6.83; today's close sits at 47% of that range, 43.9% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — PRLD rises 1.1% to $3.81
- Closed at $3.81, +1.06% vs the prior close of $3.77. Day range $3.68–$3.82, opened at $3.78.
- Volume was 382.40K shares, 0.7x its 50-day average of 525.96K.
- Price is -23.5% vs its 50-day average ($4.98) and -2.4% vs its 200-day average ($3.90).
- 52-week range $1.15–$6.83; today's close sits at 47% of that range, 44.2% below the 52-week high.
Oct 5, 2026 — PRLD rises 2.7% to $3.77
- Closed at $3.77, +2.72% vs the prior close of $3.67. Day range $3.55–$3.81, opened at $3.68.
- Volume was 324.30K shares, 0.6x its 50-day average of 525.16K.
- Price is -24.3% vs its 50-day average ($4.98) and -3.2% vs its 200-day average ($3.89).
- 52-week range $1.15–$6.83; today's close sits at 46% of that range, 44.8% below the 52-week high.
Oct 2, 2026 — PRLD slides 3.2% to $3.67, a 3-month low, 3 down days in a row
- Closed at $3.67, -3.17% vs the prior close of $3.79. Day range $3.63–$3.82, opened at $3.75.
- Volume was 742.00K shares, 1.4x its 50-day average of 514.43K.
- Price is -26.3% vs its 50-day average ($4.98) and -5.5% vs its 200-day average ($3.88).
- 52-week range $1.15–$6.83; today's close sits at 44% of that range, 46.3% below the 52-week high.
- That makes 3 straight losses.
PRLD latest news & SEC filings
Every SEC filing by or about PRLD in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $5.70M (prior year $0)
- Net income: -$13.92M (prior year -$31.23M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.14 (prior year -$0.41) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 8, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade PRLD
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 10, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.31% (largest 11.1%). That is a volatile stock.
- Liquidity: about 498.11K shares (≈$1.62M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $3.26 vs a range of $1.16–$6.83 (37% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Genesis Gp Llc Orbimed bought 1,689,189 shares on Apr 21, 2026.
- Latest filings: 8-K Sep 10, 2026; 10-Q Aug 11, 2026; 8-K Aug 11, 2026.
- Share count: 79.80M shares outstanding (Aug 6, 2026), +41.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PRLD market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.32 | 3.41 | 3.19 | 3.26 | 479.27K |
| Oct 15, 2026 | 3.30 | 3.44 | 3.20 | 3.32 | 400.30K |
| Oct 14, 2026 | 3.50 | 3.50 | 3.20 | 3.23 | 489.00K |
| Oct 13, 2026 | 3.74 | 3.90 | 3.43 | 3.56 | 674.40K |
| Oct 12, 2026 | 3.91 | 3.94 | 3.74 | 3.74 | 196.50K |
| Oct 9, 2026 | 3.87 | 4.03 | 3.85 | 3.89 | 341.60K |
| Oct 8, 2026 | 3.77 | 3.95 | 3.66 | 3.88 | 423.50K |
| Oct 7, 2026 | 3.84 | 3.93 | 3.69 | 3.83 | 454.60K |
| Oct 6, 2026 | 3.78 | 3.82 | 3.68 | 3.81 | 382.40K |
| Oct 5, 2026 | 3.68 | 3.81 | 3.55 | 3.77 | 324.30K |
| Oct 2, 2026 | 3.75 | 3.82 | 3.63 | 3.67 | 742.00K |
| Oct 1, 2026 | 3.90 | 3.94 | 3.59 | 3.79 | 502.50K |
| Sep 30, 2026 | 4.02 | 4.02 | 3.86 | 3.91 | 702.60K |
| Sep 29, 2026 | 3.95 | 4.00 | 3.83 | 3.96 | 457.90K |
| Sep 28, 2026 | 3.85 | 3.98 | 3.72 | 3.91 | 496.20K |
| Sep 25, 2026 | 4.00 | 4.05 | 3.83 | 3.88 | 336.20K |
| Sep 24, 2026 | 4.31 | 4.32 | 3.86 | 3.99 | 1.04M |
| Sep 23, 2026 | 4.85 | 4.87 | 4.16 | 4.31 | 704.30K |
| Sep 22, 2026 | 4.70 | 4.91 | 4.63 | 4.85 | 424.40K |
| Sep 21, 2026 | 4.88 | 4.91 | 4.69 | 4.70 | 390.30K |
About Prelude Therapeutics
Prelude Therapeutics (PRLD) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WILMINGTON, DE. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1678660.
PRLD board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | Jun 10, 2026 |
| Bros. Advisors Lp Baker | Director | Jun 10, 2026 |
| Felix Baker | Director | Jun 10, 2026 |
| Julian Baker | Director | Jun 10, 2026 |
| Martin Babler | Director | Jun 10, 2026 |
| Bros. Advisors (Gp) Llc Baker | Director | Jun 10, 2026 |
| Brothers Life Sciences Lp Baker | Director | Jun 10, 2026 |
| David P Bonita | Director | Jun 10, 2026 |
| Katina Dorton | Director | Jun 10, 2026 |
| Paul A Friedman | Director | Jun 10, 2026 |
| Advisors Llc Orbimed | Director | Apr 23, 2026 |
| Capital Llc Orbimed | Director | Apr 23, 2026 |
| Capital Gp Vi Llc Orbimed | Director | Apr 23, 2026 |
| Genesis Gp Llc Orbimed | Director | Apr 23, 2026 |
| Victor Sandor | Director | Jun 10, 2026 |
| Krishna Vaddi | CEO | Feb 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sean P. Brusky | Chief Business Officer | Mar 19, 2026 |
| Andrew Combs | Chief Chemistry Officer | Feb 5, 2026 |
| Jane Huang | President, CMO | Oct 7, 2025 |
| Bryant David Lim | CLO, CFO, Corp Sec. | Feb 5, 2026 |
| Charles Q Morris | Chief Medical Officer | May 4, 2026 |
| Peggy Scherle | Chief Scientific Officer | Feb 5, 2026 |
| Krishna Vaddi | CEO | Feb 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 21, 2026 | Genesis Gp Llc Orbimed | Buy | 1,689,189 | $4.44 |
| Apr 21, 2026 | Genesis Gp Llc Orbimed | Buy | 1,126,126 | $4.44 |
| Apr 21, 2026 | Genesis Gp Llc Orbimed | Buy | 1,689,189 | $4.44 |
| Apr 21, 2026 | Genesis Gp Llc Orbimed | Buy | 1,126,126 | $4.44 |
| Apr 21, 2026 | Advisors Llc Orbimed | Buy | 1,689,189 | $4.44 |
| Apr 21, 2026 | Advisors Llc Orbimed | Buy | 1,126,126 | $4.44 |
| Apr 21, 2026 | Advisors Llc Orbimed | Buy | 1,689,189 | $4.44 |
| Apr 21, 2026 | Advisors Llc Orbimed | Buy | 1,126,126 | $4.44 |
| Apr 21, 2026 | Capital Gp Vi Llc Orbimed | Buy | 1,689,189 | $4.44 |
| Apr 21, 2026 | Capital Gp Vi Llc Orbimed | Buy | 1,126,126 | $4.44 |
| Apr 21, 2026 | Capital Gp Vi Llc Orbimed | Buy | 1,689,189 | $4.44 |
| Apr 21, 2026 | Capital Gp Vi Llc Orbimed | Buy | 1,126,126 | $4.44 |
| Apr 21, 2026 | Capital Llc Orbimed | Buy | 1,689,189 | $4.44 |
| Apr 21, 2026 | Capital Llc Orbimed | Buy | 1,126,126 | $4.44 |
| Apr 21, 2026 | Capital Llc Orbimed | Buy | 1,689,189 | $4.44 |
PRLD financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $12.14M | $-99.50M | -1.29 | $-56.30M |
| Dec 31, 2024 | $7.00M | $-127.17M | -1.68 | $-102.89M |
| Dec 31, 2023 | — | $-121.83M | -2.02 | $-107.06M |
| Dec 31, 2022 | — | $-115.44M | -2.44 | $-83.73M |
| Dec 31, 2021 | — | $-111.69M | -2.43 | $-83.53M |
Latest balance sheet: total assets $189.36M, total liabilities $55.63M, cash $26.33M (as of Jun 30, 2026).
PRLD earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $5.32 |
| May 12, 2026 | 8-K Item 2.02 (results) | $4.64 |
| Mar 10, 2026 | 8-K Item 2.02 (results) | $3.60 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.47 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $0.94 |
| May 6, 2025 | 8-K Item 2.02 (results) | $0.80 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $0.67 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $1.32 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 15, 2024 | 8-K Item 2.02 (results) | — |
| Nov 1, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PRLD
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.